Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

saccharomyces boulardii and Reduced Diarrhea

Research synthesisHigh evidenceMixed effect size8 studies · 8 beneficial · 0 neutral · 0 harmful

Across 8 studies, all reported beneficial effects of Saccharomyces boulardii on reducing diarrhea, with effect sizes ranging from small to large. The evidence shows moderate-to-large effects in clinical populations, particularly for preventing antibiotic-associated diarrhea and reducing diarrhea during Helicobacter pylori eradication therapy, with doses commonly around 250–500 mg/day. Most studies involved patients with specific clinical conditions (e.g., pelvic radiotherapy, Helicobacter pylori infection, critically ill tube-fed patients), rather than healthy adults.

  • Effective dose range: 250–500 mg/day (or up to 500 mg four times a day)
  • Studied populations: patients undergoing pelvic radiotherapy, patients with Helicobacter pylori infection, critically ill tube-fed patients, hospitalized patients

Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Many studies did not report the form of S. boulardii, so no conclusions can be drawn about form-specific effects. The evidence base is moderately sized (8 studies) but consists largely of clinical populations, so generalizability to healthy adults is uncertain.

Generated Jun 11, 2026
Doses used in studies
  • mg/day: 250–2,000 (median 1,125, IQR 687.5–1,562.5) — 2 studies
Safety in these studies
8 of 8 papers
Back to top